CBX4 suppresses CD8 + T cell antitumor immunity by reprogramming glycolytic metabolism
Theranostics · 2024
DOI: 10.7150/thno.95748 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, 2024. Verfasst von Jingzeng Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ T…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Glycolysis, Tumor Microenvironment, Mice, Knockout. Die Arbeit wurde bisher 28-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Rationale
CD8+ T cells undergo a series of metabolic reprogramming processes during their activation and proliferation, including increased glycolysis, decreased aerobic oxidation of sugars, increased amino acid metabolism and increased protein synthesis. However, it is still unclear what factors regulate these metabolic reprogramming processes in CD8+ T cells in the tumor immune microenvironment.
Methods
T cell chromobox protein 4 (CBX4) knock-out mice models were used to determine the role of CBX4 in CD8+ T cells on the tumor immune microenvironment and tumor progression. Flow cytometry, Cut-Tag qPCR, Chip-seq, immunoprecipitation, metabolite detection, lentivirus infection and adoptive T cells transfer were performed to explore the underlying mechanisms of CBX4 knock-out in promoting CD8+ T cell activation and inhibiting tumor growth.
Results
We found that CBX4 expression was induced in tumor-infiltrating CD8+ T cells and inhibited CD8+ T cell function by regulating glucose metabolism in tumor tissue. Mechanistically, CBX4 increases the expression of the metabolism-associated molecule aldolase B (Aldob) through sumoylation of trans-acting transcription factor 1 (SP1) and Krüppel-like factor 3 (KLF3). In addition, Aldob inhibits glycolysis and ATP synthesis in T cells by reducing the phosphorylation of the serine/threonine protein kinase (Akt) and ultimately suppresses CD8+ T cell function. Significantly, knocking out CBX4 may improve the efficacy of anti-PD-1 therapy by enhancing the function of CD8+ T cells in the tumor microenvironment.
Conclusion
CBX4 is involved in CD8+ T cell metabolic reprogramming and functional persistence in tumor tissues, and serves as an inhibitor in CD8+ T cells' glycolysis and effector function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Tra…
- Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Clinical Medical Research Center of Hepatic Surgery at Hubei Province, Wuhan, China.
Zitieren
APA
Wang, J., Jia, W., Zhou, X., Ma, Z., Liu, J., & Lan, P. (2024). CBX4 suppresses CD8 + T cell antitumor immunity by reprogramming glycolytic metabolism. Theranostics. https://doi.org/10.7150/thno.95748
Vancouver
Wang J, Jia W, Zhou X, Ma Z, Liu J, Lan P. CBX4 suppresses CD8 + T cell antitumor immunity by reprogramming glycolytic metabolism. Theranostics. 2024. doi:10.7150/thno.95748
BibTeX
@article{Wang2024,
author = {Wang, Jingzeng and Jia, Wenlong and Zhou, Xi and Ma, Zhibo and Liu, Jing and Lan, Peixiang},
title = {CBX4 suppresses CD8 + T cell antitumor immunity by reprogramming glycolytic metabolism},
journal = {Theranostics},
year = {2024},
doi = {10.7150/thno.95748}
}
EUVIMED